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Abstract The 6D6 anti-cortisol scFv was prepared as fusion
protein with maltose-binding protein (MBP) to increase the
amount of soluble product. This fusion was almost completely
insoluble when produced in a wild-type strain of Escherichia coli.
However, when MBP-scFv fusion was produced in a tolR leaky
strain, it was secreted into the culture medium as an active,
soluble protein. Production of recombinant proteins in the tolR
strain greatly enhances the recovery of active protein and may be
a useful system to produce MBP fusion proteins that would
normally aggregate when produced in wild-type bacterial strains.
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1. Introduction
The production of immunoglobulin protein subunits in Es-
cherichia coli is often problematical. The proteins may be
toxic for the host cell, degraded in vivo or misfolded and
directed to inclusion bodies. In the latter case, the proteins
can be recovered by using strong chaotropic reagents followed
by refolding in vitro. However, this step is not easily per-
formed with large proteins [1,2]. In vivo, protein aggregation
during induced production can be reduced by several di¡erent
approaches. For example, higher yields of soluble protein may
be achieved by using relatively low culture temperature and by
reducing the concentration of the induction agent [3,4]. In
addition, the use of di¡erent bacterial strains can result in
changes in soluble protein production [5]. Another approach
is to fuse the gene of interest to genes of periplasmic proteins
such as the maltose-binding protein (MBP) [6,7] or alkaline
phosphatase [8].
Isolation of single-chain immunoglobulin variable fragment
(scFv) from bacteria is di¤cult because it forms aggregates in
the periplasm [9]. The aggregates are likely formed by inter-
molecular hydrophobic contacts between folding intermedi-
ates [10,11]. If these contacts could be reduced by, for exam-
ple, releasing the recombinant protein into the culture
medium, it might be possible to produce greater quantity of
functional protein. To test this hypothesis, we used a strain
mutated in the gene encoding the TolR membrane protein.
This protein is a component of the `Tol complex' which re-
quired for the transport of group A colicins and ¢lamentous
bacteriophage DNA into the bacteria (see [12] for review). All
tol strains are hypersensitive to SDS, indicating that their
membrane structure is altered. Mutations in tol genes induce
the release of periplasmic proteins into the extracellular me-
dium [12,13].
We have prepared recombinant MBP-scFv fusion by using
a leaky tolR bacterial strain. This approach resulted in the
production of soluble, active antibody fragment; a product
that was not obtainable by using wild-type bacteria strains.
2. Materials and methods
2.1. Bacterial strains, plasmids and media
TPS300, a tolR strain of E. coli K12, was obtained by insertion of a
transposon encoding resistance to chloramphenicol into the ORF3 of
the tol cluster of E. coli GM1 (ara j(lac-pro) thi/FP lac-pro) [14].
The gene coding for the anti-cortisol scFv 6D6 was ampli¢ed
from the pscFv plasmid [15], using the polymerase chain reaction
(PCR) with the following oligonucleotides: 5P-GTTACTCGCT-
GAATTCCCGGCCATGGCGGC-3P and 5P-AATCAATCAATCTA-
GATCAGATCTGGCAAAG-3P. After digestion at the EcoRI and
XbaI restriction sites (underlined), the DNA fragment was inserted
in frame at the 3P-end of the malE gene of the pMalp (New England
Biolabs) to give the pMalscFv.
Wild-type bacteria were grown at 30³C [4] in 2YT-rich medium
with ampicillin and tolR bacteria were grown in 2YT-rich medium
with ampicillin and chloramphenicol. When cultures were at an opti-
cal density of 0.5 (A
600nm
), recombinant protein production was in-
duced by addition of 10 mM maltose or 100 WM IPTG to bacterial
cultures harbouring the chromosome-coded MBP or bacterial cultures
harbouring the pscFv or pMBP-scFv plasmids, respectively.
2.2. Preparation and characterization of cellular extracts
After 2 h of induction, the bacterial culture was centrifuged and the
cell pellet resuspended directly in SDS loading bu¡er as described by
Laemmli [16]. Supernatant proteins were concentrated and washed
using Centricon 10 (Amicon). Cells were also resuspended in lysis
bu¡er (lysosyme 1 mg/ml in 100 mM Tris-HCl, pH 7.5, 1 mM
EDTA). After 30 min at 37³C, the resuspended cells were lysed by
10 freeze-thaw steps and centrifuged 30 min at 60 000Ug. The super-
natant and the pellet are referred to as the cellular soluble fraction
and the cellular insoluble fraction, respectively.
Samples corresponding to 2U10
8
cells were analyzed by 12% SDS-
PAGE and Western blotting. MBP and MBP-scFv were detected by
anti-MBP serum (New England Biolabs). scFv was detected by a
rabbit anti-Fab serum (Immunotech S.A.)
2.3. Puri¢cation of the MBP-scFv fusion
2.3.1. MBP-scFv puri¢cation by cortisol a¤nity chromatography.
Fifty millilitres of culture medium was centrifuged for 30 min at
60 000Ug and the supernatant was concentrated to 1 ml, using an
ultra ¢ltration unit. At this step, samples were diluted 10 times in
phosphate bu¡ered saline (PBS), concentrated on Centriprep 10 (Ami-
con) to 1 ml and loaded onto an a¤nity chromatography column. The
a¤nity column was prepared by adding cortisol conjugated to BSA
(Sigma) to activated A¤-gel 10 resin (BioRad) described in the man-
ufacturer's instructions. Binding e¤ciency of the column was checked
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with Fab fragments prepared from whole monoclonal 6D6 antibody.
Fab fragments were eluted with 100 mM triethanolamine.
2.3.2. MBP-scFv puri¢cation by amylose a¤nity chromatography.
Cell-free extracts containing MBP-scFv were prepared as described
above. The extracts were loaded onto amylose, washed extensively,
and eluted with 10 mM maltose.
2.4. Immunological tests
Soluble fraction and culture medium activity were tested enzyme
linked immunosorbant assay (ELISA). Biotinylated BSA-cortisol was
bound on avidin-coated microwells (Immunotech S.A.). The wells
were saturated with 2% milk in PBS. Fifty microlitres of each fraction
(corresponding to 10
9
cells) was added to wells containing 50 Wl of 4%
milk PBS (each mix was also tested after a 1:10 or 1:100 dilution in
2% milk PBS). Wells were washed 4 times with 0.1% Tween/PBS
followed by 4 times with PBS. Bound scFv or MBP-scFv fusion
were revealed by addition of rabbit anti-Fab serum followed by de-
tection with a peroxidase-conjugated anti-rabbit antibody. After in-
cubation with ABTS solution, the absorbance was measured at 405
nm. Samples isolated by amylose chromatography were also tested by
ELISA. In this case, active fusion protein was revealed by addition of
anti-MBP serum, followed by detection with a peroxidase-conjugated
anti-rabbit antibody.
Fusion protein a¤nity to cortisol was measured by equilibrium
dialysis at 4³C, essentially as described [17], but the sample volume
was reduced, using 200 Wl compartments.
125
I-labelled-cortisol was
diluted with di¡erent amounts of non-radioactive cortisol and dia-
lyzed against the concentrated proteins from the culture medium for
20 h through a dialysis membrane (Spectra/por MWCO: 6000^8000).
At equilibrium, the culture medium compartment contains the free
steroid plus the bound steroid and the opposite compartment contains
the free steroid at the same concentration. The K
d
was determined
graphically by Scatchard representation.
3. Results
3.1. Production of the scFv or MBP-scFv fusion in a wild-type
E. coli strain
We have previously shown that the 6D6 scFv fused to a
prokaryotic signal sequence accumulates within the wild-type
cells as insoluble protein aggregates (inclusion bodies) ([15]
and Fig. 1A, left side). To obtain a higher yield of functional
protein in the soluble fraction, we chose to use the MBP
fusion technique. For this purpose, we cloned the 6D6 scFv
gene into the pMalp vector to make pMalscFv. After IPTG
induction of the wild-type GM1 bacterial strain harboring
pMalscFv, the localisation of the fusion protein was studied
by Western blot visualized by an anti-MBP serum. Unfortu-
nately, although the fusion protein was produced in large
amounts, it was localised mostly in the cellular insoluble frac-
tion and was not detected in the culture medium as for the
scFv (Fig. 1B, left side). Moreover, the protein was partially
degraded, as already observed with other fusion proteins [18].
Therefore even when fused to a periplasmic protein, most of
the 6D6 scFv remained insoluble. Previous studies show that
recombinant antibody fragments tend to aggregate upon pro-
duction in the periplasm of E. coli [6,19,20]. To avoid aggre-
gation of scFv, we used E. coli tol mutants, that release the
periplasmic proteins in the culture medium [12,13].
3.2. Secretion of MBP in wild-type and tolR E. coli strain
The TPS300 strain (tolR) was chosen because its growth
rate is almost identical to that of the GM1 wild-type strain,
unlike all the other tol mutants. The extracellular localisation
of MBP in this strain was veri¢ed by immunoblotting with
rabbit anti-MBP serum. The mal operon was induced with
maltose in both tolR and wild-type strains. The MBP pro-
duced by the wild-type strain was localised only in the cellular
fraction whereas in the case of the tolR mutant, MBP was
found in both cellular and in culture medium fractions (Fig.
1C).
Thus, the tol mutant allowed the periplasmic MBP to leak
into the medium. Since the leakiness did not prevent bacterial
growth (data not shown), we investigated if the product of a
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Fig. 1. Localisation of scFv, MBP-scFv and MBP in the wild-type (wt) and tolR strains. Bacteria harboring the pscFv (A) or pMalscFv (B)
plasmid were induced 2 h with IPTG. Bacteria without plasmid (C) were induced 2 h with maltose. Proteins were transferred onto nitrocellu-
lose and immunoblot analysis were carried out using anti-Fab (A) or anti-MBP (B,C) serum. Lane c: whole cells; lane i: insoluble cellular frac-
tion; lane s: soluble cellular fraction; lane cm: concentrated culture medium (all samples corresponded to 2U10
8
cells). Lane p: fractions
eluted from the a¤nity column of cortisol. MBP

corresponds to the MBP part of the degraded MBP-scFv fusion.
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fusion between the MBP and the scFv could be released into
the culture medium in the same way.
3.3. Production of scFv and MBP-scFv fusion in the tolR
E. coli strain
3.3.1. Localisation. After induction, the localisation of the
MBP-scFv fusion in tolR and wild-type E. coli strains was
compared by Western blotting. To serve as a control, scFv
protein (not as a fusion protein) was produced in the same
way. In both strains, a large amount of MBP-scFv as well as
scFv protein were insoluble and only traces of MBP-scFv
were detected in the soluble fractions (Fig. 1B). Furthermore,
neither scFv protein nor MBP-scFv were detected in the cul-
ture medium of the wild-type strain. However, the fusion pro-
tein was present in large amounts in the culture medium of the
tolR strain (Fig. 1B). Under similar condition no scFv was
detected in the culture medium (Fig. 1A). The MBP part of
the degraded MBP-scFv fusion (MBP

) was also released and
could be detected by Western blot analysis with anti-MBP
serum as faster migrating protein. Thus, we showed that in
the tolR mutant strain, soluble MBP-scFv could be released
from the periplasm to the culture medium, as is the case for
wild-type MBP.
3.3.2. Activity of scFv protein and MBP-scFv. The activity
of scFv and MBP-scFv proteins localised in soluble fractions
or in culture medium of both strains were analyzed by ELISA
(Fig. 2). Bound proteins were revealed with anti-Fab serum in
all cases. For scFv, a very weak signal was obtained with the
wild-type soluble fraction. The other signals were considered
as being not signi¢cant. In the case of the MBP-scFv, a strong
signal (1.3 OD
405
) was obtained with the culture medium of
the tolR strain. Signals obtained with other MBP-scFv frac-
tions (wild-type or tolR strain) were not signi¢cant. These
results suggested that a part of the MBP-scFv fusion released
by the tolR strain was active.
3.4. Puri¢cation of soluble MBP-scFv
The fusion protein was puri¢ed from culture medium by
a¤nity chromatography on BSA-cortisol-coated resin. SDS-
PAGE analysis of fractions eluted from the column revealed
one protein which corresponded to the complete fusion pro-
tein (Fig. 1B, lane p).
We also attempted to purify the fusion protein from culture
medium by amylose a¤nity column chromatography. As
shown in Fig. 3, elution of the column with maltose released
MBP-scFv and the MBP

. In fraction 4 (Fig. 3), the full-
length fusion protein was almost pure, although some de-
graded fragments were detected in other fractions. Analysis
of anti-cortisol activity by ELISA revealed that high activity
co-eluted with the full-length fusion protein.
3.5. A¤nity of the MBP-scFv fusion
The dissociation constant of the MBP-scFv cortisol com-
plex was determined by equilibrium dialysis. The value ob-
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Fig. 2. Cortisol binding activity. The activities of 50, 5 or 0.5 Wl of
soluble fractions (white bars) or concentrated culture medium (grey
bars) of both wild-type (wt) and tolR strains producing the scFv or
MBP-scFv were determined by ELISA. Bound proteins were re-
vealed using the anti-Fab serum.
Fig. 3. Puri¢cation of the MBP-scFv fusion protein. Sample corresponding to 50 ml of the culture medium was loaded onto an amylose col-
umn (lane S). Ten microlitres of each fraction eluted with 10 mM maltose (lanes 1^11) was analysed by SDS-PAGE and revealed by Coomas-
sie-blue staining (bottom) or was analysed by ELISA (top) using the anti-MBP serum. MBP

corresponds to the MBP part of the degraded
MBP-scFv fusion.
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tained, 2U10
38
M, was similar to those determined for the
scFv alone (5U10
38
M) and for the 6D6 monoclonal anti-
body (10
38
M) [15].
By this procedure we routinely puri¢ed 1 mg of soluble,
active protein from 1 l of culture medium. Under similar
conditions using the GM1 wild-type strain, less than 50 Wg
of pure scFv, could be isolated.
4. Discussion
We describe a procedure to increase the solubility of a
periplasmic MBP-scFv fusion. Many heterologous proteins
that contain disulphide bonds are inactive when produced in
E. coli because they cannot fold properly. This problem is
often encountered with the expression of scFv [15]. The lack
of eukaryotic folding catalysts (chaperones) may be responsi-
ble for abnormal hydrophobic contacts between molecules,
which may lead to aggregation. However, coexpression of
cytoplasmic chaperon proteins (GroES/L or DnaK/J) did
not improve the recovery of anti-cortisol scFv and attempts
to renature in vitro insoluble scFv were unsuccessful (data not
shown). To circumvent this problem, we produced scFv as a
fusion protein with the MBP, a well-characterised and strictly
periplasmic protein, targeted by the chaperon protein SecB to
the export machinery [21^23]. Despite these modi¢cations, the
recombinant protein produced in a wild-type E. coli strain
remained almost completely insoluble.
It has been shown that periplasmic proteins from tol E. coli
strains leak into the culture medium [13,14]. The chromo-
some-coded MBP can be recovered from the culture medium
of these mutants. We thus attempted to produce scFv or
MBP-scFv fusion in a tolR strain that, unlike the other tol
mutants, grows without cellular lysis even after induction. In
the tolR mutant, a large amount of the MBP-scFv was de-
tected in solution in the culture medium whereas no scFv
could be detected. As expected, only the culture medium of
tolR strain producing the fusion protein showed a high anti-
cortisol activity by ELISA.
The fusion protein was partially degraded in both wild-type
and tolR strains. This degradation might be due to protease
activity in the periplasm or in the outer membrane [24,25].
When the culture medium of tolR strain was loaded onto a
cortisol column, the complete fusion protein speci¢cally
bound whereas other proteins or degraded fusion protein
fragments did not bind. The same fraction was loaded onto
amylose, a saccharide that binds to native MBP. The complete
fusion protein bound to amylose. However, degradation frag-
ments of the fusion protein with full-length MBP, also bound.
This indicated that the degradation occurred in the scFv part
of the fusion protein. Moreover, if the MBP-scFv fusion was
cleaved by cytoplasmic protease in the MBP part of the mol-
ecule, it would lack the signal sequence and therefore would
not be secreted [26]. We did not attempt to use protease de-
¢cient bacterial strains because the production of MBP-scFv
fusion in these strains does not improve the recovery of full-
length protein [27]. We concluded that only the complete
MBP-scFv fusion is able to bind both cortisol and amylose.
The K
d
of the MBP-scFv fusion from the culture medium
(2U10
38
M) was almost identical to the K
d
of the original 6D6
monoclonal antibody (10
38
M). Furthermore, the a¤nity was
stronger for the scFv-MBP fusion than for the scFv protein
alone (5U10
38
M). This is consistent with previously reported
results in which it has been proposed that MBP might stabilise
scFv [18].
The TolR protein is localised in the inner membrane and
implicated in outer membrane integrity [28]. As a result, peri-
plasmic proteins are released into the culture medium. The
initial hypothesis was that periplasmic aggregation could be
reduced if the recombinant product was released into the cul-
ture medium by preventing the accumulation of periplasmic
folding intermediates. Consistent with this view we found that
MBP-scFv was aggregated in wild-type cells whereas 50% of
MBP-scFv fusion was released into the culture medium of
tolR strain. This suggested that the fusion protein was prob-
ably exported and folded correctly into the periplasm. The
remaining fusion protein was found almost completely aggre-
gated in the cells. Surprisingly, scFv was not detected in the
culture medium of tolR strain although its signal peptide was
correctly processed. The signal peptide was shown as being
cleaved only after translocation was complete; presumably it
was cleaved at an early stage during translocation implying
that at least the N-terminus of the precursor was translocated
(see [29] for review). It is possible that remaining polypeptide
chain could be blocked by incorrect folding at an earlier stage.
The e¤cient secretion of proteins through the cytoplasmic
membrane of E. coli requires chaperon proteins, such as
SecB, to maintain the precursor in a translocation-competent
conformation [21^23]. It was shown that the antifolding ac-
tivity of SecB promotes the export of MBP [21] and that the
mature part of MBP determines the dependence of the protein
on SecB for export [30]. Therefore the fusion of scFv with
MBP might be responsible for engaging SecB, and allows
the translocation of the MBP-scFv into the periplasm. In
contrast, without MBP, scFv is poorly translocated.
We developed a method to produce active recombinant
protein that would be strictly insoluble in wild-type E. coli
strain. This was achieved by using MBP fusion and a leaky
E. coli strain, tolR.
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